Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-Centre, Randomised, Double Blind, Placebo Controlled Study Evaluating the Efficacy, Safety and Pharmacokinetics of Two Doses of a Candidate Disease Modifying Anti-Rheumatic Drug (DMARD), (SMP-114 120 mg and 240 mg Once Daily), Administered in Combination With Ongoing Methotrexate Treatment in Patients With Active Rheumatoid Arthritis.

NCT00296257 is registered in ClinicalTrials.gov with Dainippon Sumitomo Pharma Europe LTd. as lead sponsor.

NCT NCT00296257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00296257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-Centre, Randomised, Double Blind, Placebo Controlled Study Evaluating the Efficacy, Safety and Pharmacokinetics of Two Doses of a Candidate Disease Modifying Anti-Rheumatic Drug (DMARD), (SMP-114 120 mg and 240 mg Once Daily), Administered in Combination With Ongoing Methotrexate Treatment in Patients With Active Rheumatoid Arthritis.
Lead sponsor
Dainippon Sumitomo Pharma Europe LTd.
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2006
Completion date
April 30, 2008
Enrollment
312 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis (ra)